Happitech

What Happitech does

Happitech, founded in 2015 and headquartered in Rotterdam, Netherlands, develops a CE-marked Class IIa Software as a Medical Device that measures heart rate, heart rate variability, and atrial fibrillation using only a smartphone camera and flash, eliminating the need for specialist hardware. The platform is built on a photoplethysmography (PPG) signal pipeline combined with proprietary AI/ML models — a shallow neural network for peak detection, a support vector machine for signal quality estimation, and rhythm classification — trained on more than 10 billion data points across 88 countries and validated at 98.1% sensitivity and specificity for AF in peer-reviewed publications.

The product is delivered as an SDK (for technology partners such as Luscii, Huma, and Ortus-iHealth to embed into remote patient monitoring and virtual ward platforms), a white-label Module with pre-built UI, the FastStart Research App for clinical researchers (deployed at institutions including Mount Sinai, Boston Children's Hospital, and Vrije Universiteit Amsterdam), and a direct-to-patient Heart Rhythm App launched in 2025. Hardware-free, the technology is positioned against Holter/patch devices at a 90% lower capital cost and is integrated into clinical pathways at St Antonius Hospital, OLVG, and Imperial College Healthcare NHS Trust, with screening deployments in the Dutch Check@Home consortium covering 160,000 individuals.

Happitech monetises primarily through SDK and module licensing to healthcare technology partners, complemented by research-licensing arrangements with academic and life science institutions and indirectly by Dutch NZa telemonitoring reimbursement (code 039133, €168–€184 per patient per 120 days). The company has been bootstrapped to date — only one disclosed non-dilutive milestone (MedTech Innovator, 2023) — and is pursuing FDA 510(k) clearance to enable US expansion. It operates from Rotterdam with an 11–50 person team and a leadership bench including a CMO who is a practicing electrophysiologist.

Name

Happitech

Legal name

Anoniem B.V.

Website

https://happitech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Happitech provides a CE-marked Class IIa Software as a Medical Device that uses a smartphone camera and AI to detect atrial fibrillation, heart rate, and heart rate variability without additional hardware. It sells this capability as an SDK and module to remote patient monitoring platforms, hospitals, clinical researchers, and patients across Europe, the UK, Australia, and South Africa.

Ownership category

akta.pro rank

Product category

Cardiac Monitoring Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)

akta.pro primary industry

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF)

Keywords

• Heart rhythm monitoring
• Atrial fibrillation detection
• Remote patient monitoring
• Photoplethysmography software
• Cardiac digital health

Headquarters

HQ city

Rotterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. SDK / Module Licensing to Technology Partners: Happitech licenses its SDK or module to technology partners (e.g., Luscii, Huma, Ortus-iHealth) who embed hardware-free heart health monitoring into their remote patient monitoring platforms, virtual wards, and health apps. Partners integrate the SDK/module into their platforms for healthcare provider and patient use.
2. FastStart Research App for Clinical Researchers: Clinical researchers use the FastStart Research App for remote heart health data collection in clinical studies. Revenue likely derived from research licensing or service fees.
3. Healthcare Provider Telemonitoring Reimbursement: Dutch healthcare providers using Happitech technology can claim NZa reimbursement code 039133 for telemonitoring (e.g., heart rhythm detection and AF monitoring), at €168.06-€184.87 per patient per 120 days, covered by all Dutch health insurers. Happitech benefits indirectly as provider adoption is driven by reimbursable care pathways.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Happitech develops and licenses a CE-certified Class IIa Software as a Medical Device (SaMD) Software Development Kit (SDK) that uses a smartphone's camera and flashlight combined with AI-based photoplethysmography (PPG) to measure heart rate, heart rate variability, and detect atrial fibrillation — with no additional hardware required. The SDK (and a white-label Module built on top of it) is integrated by digital health platforms such as Luscii, Huma, and Ortus-iHealth into remote patient monitoring and virtual ward pathways. Happitech also offers the FastStart Research App for clinical researchers and a patient-facing Happitech Heart Rhythm App for individuals diagnosed with atrial fibrillation.

Product overview

Happitech offers a smartphone-based heart health monitoring platform using photoplethysmography (PPG) technology. The core offering consists of the Happitech SDK (Software Development Kit) — a CE-certified Class IIa Software as a Medical Device that enables hardware-free heart rhythm detection, atrial fibrillation screening, heart rate monitoring, and heart rate variability measurement using only a smartphone camera. This SDK is integrated by technology partners (Luscii, Huma, Ortus-iHealth) into their virtual ward and remote patient monitoring platforms. The Module provides a white-label app interface built on the SDK. The FastStart Research App enables clinical researchers to rapidly deploy heart health monitoring for studies. The Happitech Heart Rhythm App is the patient-facing product for individuals diagnosed with atrial fibrillation. All products share the same underlying PPG-based AI technology with 98.1% sensitivity and specificity for AF detection.

Differentiator

Problem solved

Functional benefit

Brands

• FastStart Research App: A research application designed for clinical researchers to quickly generate heart health monitoring data for clinical studies within weeks, CE certified as a Class IIa Software Medical Device.
• Happitech Heart Rhythm App
• Happitech SDK

Products and services

• Happitech SDK Software Development Kit that integrates hardware-free heart health monitoring (heart rate, heart rate variability, atrial fibrillation detection) into health platforms, apps, and clinical workflows using only a smartphone camera and flashlight. CE-certified Class IIa Software as a Medical Device, designed for technology partners and developers.
• Happitech Module Fully functional application module with a complete user interface (look and feel) developed by Happitech on top of the SDK. Ready for direct integration into health platforms or apps as a white-label solution, including a doctor-facing dashboard, customisable questionnaires, and connected device enablement.
• FastStart Research App Research application enabling clinical researchers to gather remote heart health data within weeks for clinical studies. CE-certified Class IIa Software Medical Device, TGA approved, FDA in progress. Uses PPG for remote measurement of heart rate, HRV, and atrial fibrillation via smartphone, and includes customisable questionnaires, measurement frequency settings, and biweekly data collection summaries.
• Happitech Heart Rhythm App Patient-facing smartphone application for at-home monitoring by individuals diagnosed with atrial fibrillation. Delivers heart rhythm readings in 90 seconds using only the smartphone camera and flashlight, allowing patients to monitor AF symptoms, track results, and share feedback. Developed by AF patients for AF patients.

Quantifiable outcome

• 98.1% sensitivity and specificity for atrial fibrillation detection
• +7 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability4 records

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core.

• LusciicoreTechnology or IntegrationLuscii is a leading remote patient monitoring platform in the Netherlands, UK NHS, and Europe. Happitech's SDK is integrated into the Luscii patient app and clinician-facing dashboards across all cardiology and other pathways, featured in the Luscii Library. The partnership covers national screening programmes and clinical research projects.
• HumacoreTechnology or IntegrationOne of Happitech's first and longest-lasting technology partnerships. Provides hardware-free heart rhythm monitoring for Huma's virtual wards, remote patient monitoring for healthcare providers, and decentralised clinical trials and companion apps in Life Science. Engaged in clinical trials including the Fenland Study.
• Ortus-iHealthcoreTechnology or IntegrationOrtus-iHealth integrates Happitech into its patient app and clinician dashboard to deliver virtual cardiology wards including an AF virtual ward at Imperial College Healthcare NHS Trust. Deployments have proven to reduce length of stay, re-escalation, and 30-day readmission rates.
• Dutch Cardiovascular Alliance / Check@Home ConsortiumcoreStrategic or Co-development PartnerThe Check@Home consortium, brought together by the Dutch Cardiovascular Alliance including Happitech and Luscii, aims to screen 160,000 individuals aged 50-75 across four Dutch regions for atrial fibrillation. The goal is to develop a roadmap and infrastructure for a national programme for early detection and treatment of CVD, chronic kidney disease, and type-2 diabetes.
• Dutch Heart Foundation (Hartstichting)coreStrategic or Co-development PartnerIn 2018, Happitech partnered with the Dutch Heart Foundation to launch the Heart for Heart campaign — collecting 5 years of heart rhythm research data in 7 days. This campaign formed the scientific validation foundation for Happitech's smartphone-based AF monitoring technology, spanning 88 countries and 1,200+ locations worldwide.
• St Antonius HospitalcoreStrategic or Co-development PartnerSt Antonius Hospital developed an integrated remote patient monitoring pathway for post-AF ablation patients using Happitech technology via the Luscii platform. The pathway handles 35 new patients per month, has treated 1,000+ patients, reduced cardiology team workload, and increased AF-ablation service capacity.
• OLVG HospitalcoreStrategic or Co-development PartnerOLVG integrated Happitech hardware-free heart health monitoring into its Hartcentrum app combined with the Luscii platform, with the goal of offering 50% of patients digital-first healthcare options.
• Mount SinaicoreStrategic or Co-development PartnerHappitech has a research partnership with Mount Sinai for clinical validation and real-world evidence generation using its PPG technology.
• Boston Children's HospitalcoreStrategic or Co-development PartnerHappitech has a research partnership with Boston Children's Hospital as part of its network of leading hospitals and academic institutions for clinical research.
• UMC UtrechtcoreStrategic or Co-development PartnerHappitech has a research partnership with UMC Utrecht for clinical validation of its heart health monitoring technology.
• Vrije Universiteit AmsterdamcoreStrategic or Co-development PartnerVrije Universiteit Amsterdam researchers used Happitech SDK in the EVA App for monitoring stress and smoking cessation in pregnant women in a randomised controlled trial (Stress- and Smoke-free Pregnancy Study). PPG proved highly suitable for HRV-biofeedback assessments.
• Imperial College Healthcare NHS TrustcoreStrategic or Co-development PartnerImperial College Healthcare NHS Trust deployed an atrial fibrillation virtual ward using Happitech via Ortus-iHealth. Deployments across the Trust and North West London have reduced length of stay, re-escalation, and 30-day readmission rates.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Eko Health: Eko Health builds digital stethoscopes and AI-powered cardiac/Lung sound analysis (FDA-cleared) with telehealth and RPM workflows for clinicians. It is an emerging AI-cardiac-diagnostics player with a hardware-plus-software model and provider focus, comparable in clinical positioning and FDA-cleared SaMD pathway even though its core device form factor differs.
• CardiacSense: CardiacSense develops a wearable (watch/wristband) for continuous AF and vital sign monitoring with CE/FDA pursuit. It is an emerging player in continuous cardiac monitoring whose wearable form factor competes for clinical attention in the same RPM/AF categories Happitech serves via smartphone PPG.

Broad incumbents

• Withings: Withings offers connected health devices (ScanWatch, Body Cardio) with ECG and AF detection, plus a health platform for partners. It competes indirectly in the consumer/clinical heart-monitoring space and is a relevant incumbent comparable for the broader category Happitech operates in, though Happitech's hardware-free PPG approach is differentiated.
• Preventice Solutions (Boston Scientific): Preventice (acquired by Boston Scientific) provides BodyGuardian remote cardiac monitoring with AI-based arrhythmia classification for hospitals and clinicians. It is a broader incumbent in the remote cardiac monitoring category that Happitech's cheaper, hardware-free RPM offering targets as a value-based alternative.
• Apple (Apple Watch Heart Health): Apple Watch ECG and irregular rhythm notification features (FDA-cleared) are the highest-reach consumer AF detection competitor globally. While Apple pairs the feature with a hardware device, it shapes provider and patient expectations for what smartphone/wearable AF monitoring looks like and can either compete with or pull demand through to clinical-grade software like Happitech depending on clinical positioning.
• iRhythm Technologies (Zio): iRhythm's Zio is a clinical-grade ambulatory cardiac monitor with AI-based arrhythmia detection. It represents the established, hardware-based clinical cardiac monitoring alternative that Happitech's smartphone-PPG approach is positioned against on cost and convenience, making iRhythm a key reference point for the incumbent category Happitech is disrupting.

Others

• Huma (formerly Medopad): Huma is a virtual ward and decentralized clinical trial platform that integrates Happitech as its heart-rhythm layer. It is both a key integration partner and a complementary platform reaching similar hospital and research customers. Like Luscii, Huma is an adjacent platform player whose commercial success directly amplifies Happitech SDK adoption, making it highly relevant for ecosystem context.
• Luscii: Luscii is Happitech's lead virtual ward/RPM platform partner in the Netherlands and UK, but it is also a strategic partner/customer embedding Happitech in its own product. They co-develop clinical pathways and Happitech is embedded across Luscii cardiology routes. The relationship is partner-customer-channel, not a head-to-head competitor in heart-rhythm detection, but Luscii is the most relevant adjacent player for understanding Happitech's distribution moat.

Direct peers

• FibriCheck: FibriCheck is a CE-marked smartphone PPG algorithm for AF detection, with a direct API/SDK and white-label offering for healthcare providers and insurers across Europe. It is the closest head-to-head on Happitech's core model: software-only PPG AF detection, OEM/SDK licensing to virtual care platforms, and European health system deployments - making it the most analogous direct peer.
• AliveCor: AliveCor (KardiaMobile) is the most direct competitor - a FDA-cleared, smartphone-based ECG/AF detection device and platform. Both companies target AF detection via smartphone, sell to clinicians and patients, and have cleared medical-device regulatory pathways. They are the closest substitute for Happitech's hardware-free smartphone PPG approach, though AliveCor pairs it with a hardware ECG snap rather than using only the camera.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Happitech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Happitech